Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Razan Mohty, Yenny Moreno Vanegas, Michael G. Heckman, Hassan B. Alkhateeb, Alexander P. Hochwald, William J. Hogan, Mohamed A. Kharfan-Dabaja, Rhett P. Ketterling, Nandita Khera, Mark R. Litzow, Abhishek A. Mangaonkar, Hemant S. Murthy, Jeanne M. Palmer, Mithun V. Shah, Lisa Z. Sproat, David S. Viswanatha, James M. Foran

Blood (2022) 140 (Supplement 1): 4863–4864.

https://doi.org/10.1182/blood-2022-168053

Published: 2022

Journal Articles

Higher Skeletal Muscle Index Is Associated with Improved Overall Survival in Older Patients with Sarcopenia Undergoing Allogeneic Stem Cell Transplant

Charles Gaulin, Blake T. Langlais, Luke Mountjoy, Panagiotis Korfiatis, Nelly Tan, Jose F. Leis, Nandita Khera, Pierre Noel, Lisa Z. Sproat, Tania Jain, Jeanne M. Palmer

Blood (2021) 138 (Supplement 1): 3960.

https://doi.org/10.1182/blood-2021-149274

Published: 2021

Journal Articles

Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC)

James M. Foran, Michael G. Heckman, Yesesri Cherukuri, Mikolaj Wieczorek, Zaid Abdel Rahman, Liuyan Jiang, Hemant S. Murthy, Laura Finn, Talha Badar, Lisa Z. Sproat, Yanyan Lou, James R. Cerhan, Yan Asmann

Blood (2021) 138 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2021-151233

Published: 2021

Journal Articles

DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41 : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort

Talha Badar, Ahmad Nanaa, Rong He, Aref Al-Kali, David S. Viswanatha, Emily Godsey, Lisa Z. Sproat, Mohamed A. Kharfan-Dabaja, Mrinal M. Patnaik, Hassan B. Alkhateeb, Mark R. Litzow, James M. Foran

Blood (2021) 138 (Supplement 1): 3693.

https://doi.org/10.1182/blood-2021-145115

Published: 2021

Journal Articles

Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience

Ahmad Nanaa, Aref Al-Kali, David S. Viswanatha, James M. Foran, Talha Badar, Lisa Z. Sproat, Rong He, Phuong L Nguyen, Dragan Jevremovic, Mohamed E Salama, Patricia Greipp, Naseema Gangat, Ayalew Tefferi, Mark R. Litzow, Abhishek A. Mangaonkar, Mithun V. Shah, Mrinal M. Patnaik, Hassan B. Alkhateeb

Blood (2021) 138 (Supplement 1): 3691.

https://doi.org/10.1182/blood-2021-144400

Published: 2021

Journal Articles

Molecular Epidemiology of AML: Association of Somatic Gene Mutations with Epidemiologic Exposures and Outcomes in the Mayo Clinic AML Epidemiology Cohort

Zaid Abdel Rahman, MD, Yesesri Cherukuri, Michael G. Heckman, Laura E. Finn, MD, Liuyan Jiang, MD, Lisa Z. Sproat, MD, James R. Cerhan, MD PhD, Yan Asmann, PhD, James M. Foran, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-134353

Published: 2020

Journal Articles

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Yazan Numan, MD, Zaid Abdel Rahman, MD, Justin Grenet, MD, Stephanie Boisclair, MD, Jan Philipp Bewersdorf, MD, Dylan Barth, PharmD, BCPS, Amer M. Zeidan, MBBS, MHS, Musa Yilmaz, MD, Shira Dinner, MD, Yehuda E. Deutsch, MD, Olga Frankfurt, MD, Mark Litzow, MD, Aref Al-Kali, MD, James M. Foran, MD, Lisa Z. Sproat, MD, Borko Jovanovic, PhD, Naval Daver, MD, Alexander E. Perl, MD, Jessica K. Altman, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-137251

Published: 2020

Journal Articles

Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype

Sharad Khurana, MDMSc, Michael G. Heckman, Jordan Cochuyt, Fiona E. Craig, MBBS, Zaid Abdel Rahman, MD, Patricia Greipp, DO, Lisa Z. Sproat, MD, Mark Litzow, MD, James M. Foran, MD, Liuyan Jiang

Blood (2019) 134 (Supplement_1): 5210.

https://doi.org/10.1182/blood-2019-123286

Published: 2019

Journal Articles

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Zaid Abdel Rahman, MD, Michael G. Heckman, Kevin C. Miller, BS, Patricia Greipp, DO, Matthew R Spiegel, Sharad Khurana, MDMSc, Hassan B. Alkhateeb, MD, Mrinal M Patnaik, MDMBBS, Lisa Z. Sproat, MD, Liuyan Jiang, Vivek Roy, MD, Mark Litzow, MD, Mohamed A Kharfan-Dabaja, MDMBA, William J Hogan, MB, BCh, James M. Foran, MD

Blood (2019) 134 (Supplement_1): 2588.

https://doi.org/10.1182/blood-2019-122068

Published: 2019

Journal Articles

Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC

Caleb J Scheckel, DO, Megan Meyer, MD, Lanyu Mi, MS, James L. Slack, MD, Pierre Noel, MD, Jose F. Leis, MD PhD, Lisa Z. Sproat, James M. Foran, MD, Aref Al-Kali, MD, Rhett P. Ketterling, William J. Hogan, MB, BCh, Mark R. Litzow, MD, Jeanne Palmer, MD

Blood (2018) 132 (Supplement 1): 2678.

https://doi.org/10.1182/blood-2018-99-114655

Published: 2018

Journal Articles

Does Early T Cell Chimerism Predict Outcomes after Allogeneic Hematopoietic Cell Transplantation ?

Tania Jain, MD, Luke Mountjoy, DO, Katie L. Kunze, PhD, Pierre Noel, MD, Nandita Khera, MD, Jose F. Leis, MD PhD, James L. Slack, MD, Lisa Z. Sproat, Jeanne Palmer, MD

Blood (2018) 132 (Supplement 1): 3360.

https://doi.org/10.1182/blood-2018-99-115287

Published: 2018

Journal Articles

Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort

César J. Torres-Gutierrez, BS, Michael G. Heckman, Ryan A. Hlady, Rhett P. Ketterling, Lisa Z. Sproat, Kathryn E. Pearce, Elizabeth R. Lesser, Nancy N. Diehl, Laura E. Finn, Liuyan Jennifer Jiang, Keith D. Robertson, James R. Cerhan, MD PhD, James M. Foran, MD

Blood (2018) 132 (Supplement 1): 3987.

https://doi.org/10.1182/blood-2018-99-119386

Published: 2018

Journal Articles

Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG

Luke Mountjoy, DO, Katie L. Kunze, PhD, Tania Jain, MD, James L. Slack, MD, Nandita Khera, MD, Jose F. Leis, MD PhD, Pierre Noel, MD, Lisa Z. Sproat, Jeanne Palmer, MD

Blood (2018) 132 (Supplement 1): 5715.

https://doi.org/10.1182/blood-2018-99-112217

Published: 2018

NARROW

IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Higher Skeletal Muscle Index Is Associated with Improved Overall Survival in Older Patients with Sarcopenia Undergoing Allogeneic Stem Cell Transplant

Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC)

DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41 : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort

Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience

Molecular Epidemiology of AML: Association of Somatic Gene Mutations with Epidemiologic Exposures and Outcomes in the Mayo Clinic AML Epidemiology Cohort

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC

Does Early T Cell Chimerism Predict Outcomes after Allogeneic Hematopoietic Cell Transplantation ?

Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort

Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only